Entrada Therapeutics (NASDAQ:TRDA) Trading 1.1% Higher - Still a Buy?Market Beat·Jul 10 at 12:00 AMTRDA+6.86%IVZ-3.94%
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga_article·Jun 5 at 04:06 PMTRDA+6.86%MBIO-7.19%
10:54 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAprnewswire·May 28 at 09:57 AMTRDA+6.86%
Entrada Therapeutics Highlights Transformational Year and Pipeline ProgressTip Ranks·May 19 at 05:48 AMTRDA+6.86%
Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026TradingView·May 19 at 05:03 AMTRDA+6.86%
22:30 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAprnewswire·May 14 at 09:30 PMTRDA+6.86%
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety ProfileMarket Beat·May 9 at 01:07 AMTRDA+6.86%
Entrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Expectations By $0.11 EPSMarket Beat·May 7 at 11:51 PMTRDA+6.86%
Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Whybenzinga_article·May 7 at 12:38 PMTRDA+6.86%
Entrada Therapeutics shares are trading lower after the company reported mixed Q1 financial results.benzinga_article·May 7 at 07:46 AMTRDA+6.86%
